ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 6

Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome

Lidia Ostanek1, Danuta Bobrowska - Snarska2, Barbara Nestorowicz3 and Marek Brzosko4, 1Department of Rheumatology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland, Szczecin, Poland, 2Department of Rheumatology, Pomeranian Medical University, Szczecin, Poland, Szczecin, Poland, 3Department of Pathological Obstetrics and Delivery, Pomeranian Medical University , Szczecin, Poland, Szczecin, Poland, 4Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome and pregnancy

  • Tweet
  • Email
  • Print
Session Information

Title: Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose:

  1. To analyse risk factors for obstetric pathology in patients with antiphospholipid syndrome (APS).
  2. To assess the effectiveness of treatment depending on pharmacotherapy.  

Methods:

The courses of 275 pregnancies and deliveries in patients with diagnosed APS (PAPS-68, SAPS-41 patients) were analysed. 101 pregnancies were treated according to current recommendations. The treatment was consistently followed up with both a rheumatologist and an obstetrician. A retrospective analysis of previous pregnancies and deliveries, both treated and untreated was conducted. The immunological profile of the patients (ANA, SS-A, SS-B, Ro52, lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti β2GPI (aβ2GPI), antiprothrombin antibodies (aPTR), anti-phosphatidylserine (aPS), complement component 3 and complement component 4) was investigated. Assessment of metabolic and environmental factors influencing pregnancy (smoking, arterial hypertension, lipid profile, hyperglycaemia, uric acid concentration) was carried out. Yate’s chi-sqared test, Pearson’s ch-sqared test, Spearman’s rank correlation and logistic regression analysis were used to conduct the statistical analysis.   

Results:

Risk factors for unsuccessful pregnancy included: young age at the diagnosis and during pregnancy (p<0,001), presence of LA (p=0,0046), aPTR (p=0,034), arterial hypertension (p=0,012), hyperuricemia (p=0,005). Miscarriages were more frequent in patients with PAPS than with SAPS (p=0,007), in patients with aCL IgM (p=0,042) and in patients treated with glucocorticosteroid (GS) (p=0,027). Premature births were more frequent in young patients (p=0,002), with SAPS (p=0,005), with presence of ANA (p=0,0026), LA (p=0,045), low concentration of C3 (p=0,006), patients with smoking history (p=0,018) and those treated with GS (p=0,000). The presence of LA involved the risk of fetal death (p=0,027). Chances of successful pregnancy were enhanced by: the application of low molecular weight heparin (LMWH)(p=0,000),aspirin (ASA) (p=0,001), combined treatment: LMWH+ASA (p=0,002), and immunoglobulins iv (p=0,002).  

Conclusion:

1.The occurrence of aPL and diagnosis of APS increase the risk of obstetric pathology.

2. Apart from immunologic factors (aCL, LA, aPTR,↓C3), there are other factors which determine the risk of pregnancy failure, i.e. demographic factors (age), environmental factors (smoking, hyperuricemia) and associated treatment (GS).

3. PAPS increases the risk of miscarriage, SAPS increases the risk of premature birth.

4. Treating APS patients with ASA, LMWH, and in justified cases with immunoglobulins iv, increases the chances of successful pregnancy.


Disclosure:

L. Ostanek,
None;

D. Bobrowska – Snarska,
None;

B. Nestorowicz,
None;

M. Brzosko,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/researchers-own-experience-in-managing-obstetric-complications-in-pregnant-women-with-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology